|
| Exchange Received Time 27/04/2018 19:38:33 Exchange Disseminated Time 27/04/2018 19:38:40 Time Taken 00:00:07 | Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the outcome of the meeting of Board of Directors of the Company held today, April 27, 2018 is as follows, in summary, details are available in the attached letter:
1. Approval of unaudited financial results for the 1st quarter March 31, 2018:
2. Approval to enter into business transfer agreement to sell biopharma, performance materials and life science (the BPL Business) to MLSPL for total consideration of INR 10,520,000,000 in terms of the BTA.
3. Entering into certain commercial agreements with one or more entities belonging to Merck group.
4. Approved issuance of Postal Ballot Notice to seek shareholders'' approvals for implementing the above decisions.
5. Constituted the committee of independent directors to provide a reasoned recommendation on the open offer. |
|
|